Charlottenlund, Denmark

Keld Danø


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Keld Danø: A Pioneer in Cancer Research

Introduction: Keld Danø, based in Charlottenlund, Denmark, is recognized for his significant contributions to cancer research through his innovative work in developing peptide antagonists. With a focus on enhancing therapeutic methods for treating cancer, Danø’s unique approach to targeting specific receptors has paved the way for advancements in cancer treatment.

Latest Patents: Keld Danø holds a patent titled "Peptide antagonists of the human urokinase receptor and method for selecting them." This groundbreaking patent details a novel set of inhibitors designed to obstruct the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR). The invention presents a series of peptide fragments, which can be monomeric or in multiple copies linked to a common scaffold. These peptides may incorporate uncommon substituted amino acids, partially forming peptoid sequences. Notably, Danø's invention holds therapeutic potential for cancer treatment, utilizing a modified non-human mammalian receptor against which the inhibitors are antagonistic.

Career Highlights: Throughout his career, Keld Danø has dedicated himself to experimental cancer research. His innovative work has not only expanded the understanding of cancer treatment but also led to practical applications that benefit patients. Danø works within the framework of the Cancerforskningsfonden Af 1989, a foundation aimed at promoting experimental cancer research, which underscores his commitment to advancing oncology.

Collaborations: Danø has collaborated with prominent figures in the field, notably Michael Ploug and Søren Østergaard. Their joint efforts in research highlight a team dynamic focused on exploring new avenues in cancer therapies and diagnostics, ultimately enriching the landscape of scientific inquiry in this critical area.

Conclusion: Keld Danø’s contributions to the field of cancer research through his patent on peptide antagonists exemplify the vital role of innovation in medicine. His work not only offers hope for new therapeutic strategies but also sets a benchmark for future research endeavors aimed at conquering cancer. As he continues his work at Cancerforskningsfonden Af 1989, Keld Danø remains a significant figure in the ongoing battle against this challenging disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…